Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.76 |
| ▸ | MMP3 | P08254 | 3/20 | 0.76 |
| ▸ | MMP13 | P45452 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.68 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408612 | 1.00 | PKM (0.78) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL29408637 | 0.91 | MEN1 (0.68) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL29408613 | 0.91 | MEN1 (0.68) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL19736167 | 0.91 | MEN1 (0.68) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL25992865 | 0.91 | MEN1 (0.68) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL19736164 | 0.91 | MEN1 (0.68) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL21450932 | 0.89 | PKM (0.63) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL29408614 | 0.89 | MEN1 (0.66) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL19736244 | 0.89 | MEN1 (0.66) | PKMAKR1B1PTPN1MMP3MMP13 | |
| SCHEMBL19736094 | 0.89 | AKR1B1 (0.77) | PKMAKR1B1PTPN1MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468555-B1 | COMPOSITIONS FOR USE IN TREATING BACTERIAL INFECTIONS | VERSITECH LTD (HK) | 2023-08-09 | — | — | EP | disclosed |
| US-20190307729-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | VERSITECH LIMITED (HK) | 2019-10-10 | — | — | US | disclosed |
| WO-2017215552-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307729-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR USE THEREOF | NRDC, NISCH, NEK5 | PKM 1326/4885AKR1B1 3100/4885PTPN1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.